SCHEMBL3320775

SCHEMBL3320775

COc1ccc2nnc3c(C)nc(-c4cnccc4C)n3c2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 20/20 1.00
PDE10A Q9Y233 20/20 1.00
PDE3A Q14432 5/20 0.73
PDE5A O76074 1/20 0.73
PDE7A Q13946 1/20 0.73
PDE6D O43924 7/20 0.72
PDE6A P16499 7/20 0.72
PDE6G P18545 7/20 0.72
PDE6B P35913 7/20 0.72
PDE6C P51160 7/20 0.72
PDE6H Q13956 7/20 0.72
PDE3B Q13370 4/20 0.64
PDE4A P27815 2/20 0.60
PDE4B Q07343 2/20 0.60
PDE4C Q08493 2/20 0.60
PDE4D Q08499 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3323490 0.91 PDE2A (0.83) PDE2APDE10APDE3APDE5APDE7A
SCHEMBL3321342 0.89 PDE2A (0.81) PDE2APDE10APDE3APDE5APDE7A
SCHEMBL3319098 0.87 PDE2A (0.77) PDE2APDE10APDE3APDE5APDE7A
SCHEMBL3321141 0.86 PDE2A (0.76) PDE2APDE10APDE3APDE5APDE7A
SCHEMBL4121818 0.84 PDE10A (1.00) PDE2APDE10APDE3APDE5APDE7A
SCHEMBL3322970 0.84 PDE2A (1.00) PDE2APDE10APDE3APDE5APDE7A
SCHEMBL3326386 0.83 PDE10A (0.70) PDE2APDE10APDE3APDE5APDE7A
SCHEMBL3320916 0.81 PDE10A (0.73) PDE2APDE10APDE3APDE5APDE7A
SCHEMBL3318988 0.81 PDE2A (0.79) PDE2APDE10APDE3APDE5APDE7A
SCHEMBL3321889 0.80 PDE2A (0.83) PDE2APDE10APDE3APDE7APDE6D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120762-A1 Triazine derivatives as inhibitors of phosphodiesterases WYETH (US) 2010-05-13 US claimed
WO-2010054253-A1 TRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES BIOTIE THERAPIES GMBH (DE) 2010-05-14 WO disclosed
US-20100120762-A1 Triazine derivatives as inhibitors of phosphodiesterases WYETH (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120762-A1 Triazine derivatives as inhibitors of phosphodiesterases PDE2A, PDE5A, PDE12 PDE2A 1/4885PDE10A 13/4885PDE3A 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.